IR-Center Handelsblatt

curasan AG

News Detail

DGAP-News News vom 24.07.2018

curasan grants Private Label-Rights for Hyaluronic Acid used in Osteoarthritis Therapy

DGAP-News: curasan AG / Key word(s): Alliance

24.07.2018 / 08:40
The issuer is solely responsible for the content of this announcement.

  • Opening up additional sales potential
  • Cooperation with Leader Biomedical
  • Treatment pattern of multiple injections in line with current trend

Kleinostheim, July 24 2018 - curasan AG, Germany, a leading specialist for medical products in the field of orthobiologics has signed a private-label-agreement with Leader Biomedical to market their hyaluronic acid.

The company headquartered in Amsterdam will offer curasan' s hyaluronic acid for osteoarthritis therapy under their own brand, Hyalosyn(TM) Gel. This is a second brand name for curasan' s long-term proven and successfully marketed product Curavisc(R) that improves the lubricating and shock absorbing properties of the body's own synovial fluid.

"The two-brand-strategy will open additional buyer groups for our product", says Michael Schlenk, CEO of curasan AG. "Even more, we provide our cooperation partner with a very specific competitive edge, since our hyaluronic acid is one of the few products also indicated for spinal use."

"Not only patients with osteoarthritis of the large joints benefit from a therapy with curasan' s hyaluronic acid, but also patients with facet and sacroiliac joint arthritis. It also offers an excellent alternative to a treatment with painkillers and its many side effects", explains Gregor Siebert, Head of Marketing and Sales.

"Moreover, the market shows an obvious trend towards a more physiological treatment pattern of multiple injections as recommended by us; this means three to five injections given at weekly intervals instead of just one. Many clinicians are realizing that this therapy pattern results in a more enduring improvement for their patients," adds Florian Früh, Head of Product Management. "In addition to that, our medium molecular weight hyaluronic acid is also indicated for the treatment of stress related pain and first signs of movement limitations within active athletes and leisure sportsmen," he continues.

curasan AG and Leader Biomedical already introduced Hyalosyn(TM) Gel to Leader Biomedical' s global network of distribution partners and healthcare professionals on occasion of their Global Symposium, held on 14 and 15 June 2018 in the Netherlands.

Your contact at curasan AG:
Andrea Weidner
Head of Investor Relations & Corporate Communications
+49 6027 40 900-51

About curasan AG:
curasan develops, manufactures and markets biomaterials and medical devices in the field of bone and tissue regeneration, wound healing and osteoarthritis therapy. As a pioneer and global technology leader in the growing field of regenerative medicine, curasan is specialized primarily on biomimetic bone grafting materials for dental, oral/maxillofacial, orthopedic and spinal applications, i.e. materials mimicking biological structures. Numerous patents and a broad record of scientific publications demonstrate the clinical success of the products and the highly innovative strength of curasan. Dental and orthopaedic clinicians worldwide benefit from the broad range of the premium quality and easy to use portfolio offered by the technology leader curasan. curasan maintains its own high-tech facilities for research, development and manufacturing of biomaterials in Frankfurt/Main, Germany. In addition to its headquarters, the company has a subsidiary, curasan, Inc., in Wake Forest, near Raleigh, N.C., USA. curasan's innovative products are cleared by the US Food and Drug Administration (FDA) and many other international authorities and available in almost 50 countries worldwide. curasan AG is a public company listed in the General Standard at the Frankfurt Stock Exchange.

About Leader Biomedical
Leader Biomedical is committed to improving access to innovative biomaterials and implantable medical devices, thereby extending the reach of patients and caregivers worldwide. We contribute to the betterment of the healthcare sector by developing new technologies, delivering world-class contract manufacturing, and providing targeted therapeutic solutions for dental, spine, joint care, and sports medicine indications. (

24.07.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

show this